한글목차

레미케이드 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 26억 5,687만 달러에서 2026년에는 28억 331만 달러에 이르고, CAGR 5.5%로 성장할 전망입니다. 지난 수년간의 성장은 자가면역질환 유병률 증가, 생물학적 제제의 임상적 수용 확대, 병원 내 정맥주사 센터의 확대, 염증성 질환의 진단 정확도 향상, 전문의약품 유통의 성장에 기인하는 것으로 보입니다.

레미케이드 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 34억 3,368만 달러에 이르고, CAGR은 5.2%를 나타낼 전망입니다. 예측 기간 동안의 성장은 바이오시밀러 경쟁에 대한 수요 증가, 생물학적 제제 제조에 대한 투자 확대, 재택 투약 모델 확대, 개인 맞춤형 자가면역치료에 대한 관심 증가, 단일 클론 항체 개발의 진전 등에 기인할 것으로 보입니다. 예측 기간의 주요 동향으로는 TNF-α 억제제 치료제의 사용 증가, 자가면역질환에 대한 생물학적 제제 치료제의 도입 확대, 장기적인 질환 관리 약물에 대한 선호도 증가, 전문 수액 서비스 확대, 환자 중심의 치료 성과에 대한 집중도 강화 등을 들 수 있습니다.

자가면역질환의 유병률 증가는 향후 레미케이드 시장의 성장을 견인할 것으로 예측됩니다. 자가면역질환은 면역체계가 우리 몸의 건강한 세포, 조직, 기관을 이물질로 잘못 인식하고 공격하여 발병합니다. 자가면역질환 증가는 유전적 요인, 환경 변화, 오염물질 노출 증가, 생활습관, 진단에 대한 인식 증가 등이 복합적으로 영향을 미치는 것으로 알려져 있습니다. 레미케이드(인플릭시맙)는 류마티스 관절염, 크론병, 궤양성 대장염 등의 질환에 관여하는 주요 염증성 사이토카인인 종양괴사인자 알파(TNF-α)를 표적으로 하여 그 작용을 억제함으로써 이들 질환을 관리하는데 사용됩니다. 예를 들어, 2025년 4월 영국 공중보건국(GOV.UK)이 발표한 보고서에 따르면, 2024년 16세 이상 개인의 17.9%가 장기 근골격계(MSK) 질환을 앓고 있으며, 여성(20.0%)이 남성(15.6%)보다 더 높은 유병률을 보였습니다고 합니다. 따라서 자가면역질환 발생률 증가는 레미케이드 시장의 성장을 견인하는 요인으로 작용하고 있습니다.

레미케이드(인플릭시맙) 시장의 주요 기업들은 환자의 편의성 향상, 치료 순응도 향상, 기존 정맥주사 대비 시간 효율적 대안에 대한 수요 증가에 대응하기 위해 생물학적 제제의 피하주사 제제 등 혁신적인 솔루션 개발에 주력하고 있습니다. 피하투여형 생물학적 제제는 환자가 집에서 유지 용량을 자가 투여할 수 있기 때문에 기존 정맥주사제 대비 접근성이 뛰어나 정맥주사센터 방문 빈도를 줄일 수 있는 장점이 있습니다. 예를 들어, 2024년 3월, 미국 바이오 제약사 Celltrion USA, Inc.는 FDA가 승인한 최초의 인플릭시맙 피하주사제제인 Zymfentra(인플릭시맙-dyyb)를 출시하였습니다. 자이메펜테라는 염증성 장질환(IBD)의 일부인 중등도에서 중증의 활동성 궤양성 대장염(UC) 및 크론병(CD)을 앓고 있는 성인의 유지요법으로 적응증을 갖고 있습니다. 인플릭시맙 제제는 정맥주입 요법 후 사용이 승인되어 장기적인 질병 관리를 위한 편리한 자가투여 옵션을 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 시장 규제 상황과 투자환경

제29장 경쟁 구도와 기업 개요

제30장 세계 시장 경쟁 벤치마킹과 대시보드

제31장 주요 인수합병(M&A)

제32장 시장 잠재력이 높은 국가, 부문, 전략

제33장 부록

영문목차

Remicade (infliximab) is a biologic drug classified as a tumor necrosis factor-alpha (TNF-a) inhibitor. It is used to treat autoimmune disorders such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. By blocking TNF-a, a protein that plays a key role in inflammation, Remicade helps alleviate symptoms, prevent disease progression, and enhance the quality of life.

The primary disease indications for Remicade include Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and plaque psoriasis. Crohn's disease is a chronic inflammatory disorder of the gastrointestinal tract that often results in symptoms like abdominal pain, severe diarrhea, weight loss, and fatigue. The medication can be administered via subcutaneous, intravenous, or parenteral routes, and is used in settings such as hospitals, clinics, ambulatory care, and home care.

Tariffs are impacting the remicade market by increasing costs related to imported monoclonal antibody manufacturing equipment, active pharmaceutical ingredients, cold-chain logistics, and sterile delivery systems. Hospitals and specialty clinics in North America and Europe are most affected due to biologics import dependency, while Asia-Pacific experiences supply chain cost pressures. These tariffs elevate therapy costs and influence reimbursement dynamics. However, they are also encouraging localized biologics production, regional biosimilar development, and strengthened domestic pharmaceutical manufacturing capabilities.

The remicade market research report is one of a series of new reports from The Business Research Company that provides remicade market statistics, including remicade industry global market size, regional shares, competitors with a remicade market share, detailed remicade market segments, market trends and opportunities, and any further data you may need to thrive in the remicade industry. This remicade market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The remicade market size has grown strongly in recent years. It will grow from $2656.87 million in 2025 to $2803.31 million in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increasing prevalence of autoimmune disorders, wider clinical acceptance of biologics, expansion of hospital infusion centers, improved diagnosis of inflammatory diseases, growth in specialty pharmaceutical distribution.

The remicade market size is expected to see strong growth in the next few years. It will grow to $3433.68 million in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing demand for biosimilar competition, rising investments in biologics manufacturing, expansion of home infusion care models, growing focus on personalized autoimmune therapies, advancements in monoclonal antibody development. Major trends in the forecast period include increasing use of tnf-alpha inhibitor therapies, rising adoption of biologic treatments for autoimmune diseases, growing preference for long-term disease control drugs, expansion of specialty infusion services, enhanced focus on patient-centered treatment outcomes.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the Remicade market in the future. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells, tissues, or organs, treating them as foreign invaders. The rise in autoimmune diseases is attributed to a mix of genetic factors, environmental changes, greater exposure to pollutants, lifestyle choices, and enhanced diagnostic awareness. Remicade (infliximab) is used to manage these diseases by targeting and inhibiting tumor necrosis factor-alpha (TNF-a), a key inflammatory cytokine involved in conditions like rheumatoid arthritis, Crohn's disease, and ulcerative colitis. For example, in April 2025, GOV.UK, a UK-based public health agency, reported that in 2024, 17.9% of individuals aged 16 and over self-reported a long-term musculoskeletal (MSK) condition, with a higher incidence in females (20.0%) compared to males (15.6%). Therefore, the rising incidence of autoimmune diseases is a driving force behind the growth of the Remicade market.

Leading companies in the Remicade (infliximab) market are focusing on developing innovative solutions, such as subcutaneous formulations of biologic therapies, to meet the growing demand for improved patient convenience, better treatment adherence, and more time-efficient alternatives to traditional intravenous dosing. Subcutaneous biologics allow patients to self-administer maintenance doses at home, reducing the need for infusion-center visits and offering a more accessible option compared to conventional IV formulations. For example, in March 2024, Celltrion USA, Inc., a US-based biopharmaceutical company, launched Zymfentra (infliximab-dyyb), the first FDA-approved subcutaneous formulation of infliximab. Zymfentra is indicated as maintenance therapy for adults with moderate-to-severe active ulcerative colitis (UC) and Crohn's disease (CD), which are part of inflammatory bowel disease (IBD). Approved for use after IV induction with an infliximab product, Zymfentra offers a convenient, self-administered alternative for long-term disease management.

In September 2024, Tharimmune Inc., a US-based biopharmaceutical company, acquired a global license from Intract Pharma for an undisclosed amount. This acquisition aims to develop an oral version of infliximab, which has traditionally been administered intravenously, thereby improving patient compliance and potentially lowering healthcare costs related to long-term intravenous therapy. Intract Pharma Ltd. is a UK-based provider of infliximab.

Major companies operating in the remicade market are Janssen Biotech Inc.

North America was the largest region in the remicade market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the remicade market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the remicade market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The remicade market consists of sales of biosimilars of remicade, combination therapy products, administration tools, and packaging formats. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Remicade Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses remicade market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for remicade ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The remicade market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Disease Indication: Crohn's disease; Rheumatoid arthritis; Ankylosing spondylitis; Psoriatic arthritis; Ulcerative Colitis; Plaque psoriasis
• 2) By Route Of Administration: Subcutaneous; Intravenous; Parenteral
• 3) By End Use: Hospitals; Clinics; Ambulatory Care; Home Care
• Companies Mentioned: Janssen Biotech Inc.
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Remicade Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Remicade Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Remicade Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Remicade Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Increasing Use Of Tnf-Alpha Inhibitor Therapies
  • 4.2.2 Rising Adoption Of Biologic Treatments For Autoimmune Diseases
  • 4.2.3 Growing Preference For Long-Term Disease Control Drugs
  • 4.2.4 Expansion Of Specialty Infusion Services
  • 4.2.5 Enhanced Focus On Patient-Centered Treatment Outcomes

5. Remicade Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Ambulatory Care Centers
• 5.4 Home Care Providers
• 5.5 Infusion Therapy Centers

6. Remicade Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Remicade Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Remicade PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Remicade Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Remicade Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Remicade Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Remicade Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Remicade Market Segmentation

• 9.1. Global Remicade Market, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Crohn's Disease, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Ulcerative Colitis, Plaque Psoriasis
• 9.2. Global Remicade Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Subcutaneous, Intravenous, Parenteral
• 9.3. Global Remicade Market, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinics, Ambulatory Care, Home Care

10. Remicade Market Regional And Country Analysis

• 10.1. Global Remicade Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Remicade Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Remicade Market

• 11.1. Asia-Pacific Remicade Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Remicade Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Remicade Market

• 12.1. China Remicade Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Remicade Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Remicade Market

• 13.1. India Remicade Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Remicade Market

• 14.1. Japan Remicade Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Remicade Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Remicade Market

• 15.1. Australia Remicade Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. South Korea Remicade Market

• 16.1. South Korea Remicade Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 16.2. South Korea Remicade Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. Western Europe Remicade Market

• 17.1. Western Europe Remicade Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. Western Europe Remicade Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. UK Remicade Market

• 18.1. UK Remicade Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. Germany Remicade Market

• 19.1. Germany Remicade Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. France Remicade Market

• 20.1. France Remicade Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. Eastern Europe Remicade Market

• 21.1. Eastern Europe Remicade Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 21.2. Eastern Europe Remicade Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. North America Remicade Market

• 22.1. North America Remicade Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 22.2. North America Remicade Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. USA Remicade Market

• 23.1. USA Remicade Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 23.2. USA Remicade Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Canada Remicade Market

• 24.1. Canada Remicade Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 24.2. Canada Remicade Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. South America Remicade Market

• 25.1. South America Remicade Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 25.2. South America Remicade Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Middle East Remicade Market

• 26.1. Middle East Remicade Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Middle East Remicade Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Africa Remicade Market

• 27.1. Africa Remicade Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 27.2. Africa Remicade Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. Remicade Market Regulatory and Investment Landscape

29. Remicade Market Competitive Landscape And Company Profiles

• 29.1. Remicade Market Competitive Landscape And Market Share 2024
  • 29.1.1. Top 10 Companies (Ranked by revenue/share)
• 29.2. Remicade Market - Company Scoring Matrix
  • 29.2.1. Market Revenues
  • 29.2.2. Product Innovation Score
  • 29.2.3. Brand Recognition
• 29.3. Remicade Market Company Profiles
  • 29.3.1. Janssen Biotech Inc. Overview, Products and Services, Strategy and Financial Analysis

30. Global Remicade Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Remicade Market

32. Remicade Market High Potential Countries, Segments and Strategies

• 32.1 Remicade Market In 2030 - Countries Offering Most New Opportunities
• 32.2 Remicade Market In 2030 - Segments Offering Most New Opportunities
• 32.3 Remicade Market In 2030 - Growth Strategies
  • 32.3.1 Market Trend Based Strategies
  • 32.3.2 Competitor Strategies

33. Appendix

• 33.1. Abbreviations
• 33.2. Currencies
• 33.3. Historic And Forecast Inflation Rates
• 33.4. Research Inquiries
• 33.5. The Business Research Company
• 33.6. Copyright And Disclaimer